HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors

HBI-8000 is a small molecule inhibitor of class I HDACs and has been approved for the treatment of PTCL, ATL and, in combination with exemestane, in a subpopulation of breast cancer. Given the roles of HDACs in normal and cancerous cells, there are currently multiple clinical trials, by HUYABIO Inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Shojaei, Farbod, Goodenow, Bob, Lee, Gloria, Kabbinavar, Fairooz, Gillings, Mireille
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777117/
https://www.ncbi.nlm.nih.gov/pubmed/35070972
http://dx.doi.org/10.3389/fonc.2021.768685
_version_ 1784636992924942336
author Shojaei, Farbod
Goodenow, Bob
Lee, Gloria
Kabbinavar, Fairooz
Gillings, Mireille
author_facet Shojaei, Farbod
Goodenow, Bob
Lee, Gloria
Kabbinavar, Fairooz
Gillings, Mireille
author_sort Shojaei, Farbod
collection PubMed
description HBI-8000 is a small molecule inhibitor of class I HDACs and has been approved for the treatment of PTCL, ATL and, in combination with exemestane, in a subpopulation of breast cancer. Given the roles of HDACs in normal and cancerous cells, there are currently multiple clinical trials, by HUYABIO International, to test the efficacy of HBI-8000 in monotherapy or in combination settings in leukemias and in solid tumors. The current review is focused on the applications of HDACi HBI-8000 in cancer therapy and its potential in combination with DDR agents.
format Online
Article
Text
id pubmed-8777117
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87771172022-01-22 HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors Shojaei, Farbod Goodenow, Bob Lee, Gloria Kabbinavar, Fairooz Gillings, Mireille Front Oncol Oncology HBI-8000 is a small molecule inhibitor of class I HDACs and has been approved for the treatment of PTCL, ATL and, in combination with exemestane, in a subpopulation of breast cancer. Given the roles of HDACs in normal and cancerous cells, there are currently multiple clinical trials, by HUYABIO International, to test the efficacy of HBI-8000 in monotherapy or in combination settings in leukemias and in solid tumors. The current review is focused on the applications of HDACi HBI-8000 in cancer therapy and its potential in combination with DDR agents. Frontiers Media S.A. 2022-01-07 /pmc/articles/PMC8777117/ /pubmed/35070972 http://dx.doi.org/10.3389/fonc.2021.768685 Text en Copyright © 2022 Shojaei, Goodenow, Lee, Kabbinavar and Gillings https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Shojaei, Farbod
Goodenow, Bob
Lee, Gloria
Kabbinavar, Fairooz
Gillings, Mireille
HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors
title HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors
title_full HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors
title_fullStr HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors
title_full_unstemmed HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors
title_short HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors
title_sort hbi-8000, huyabio lead clinical program, is a selective histone deacetylase inhibitor with therapeutic benefits in leukemia and in solid tumors
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777117/
https://www.ncbi.nlm.nih.gov/pubmed/35070972
http://dx.doi.org/10.3389/fonc.2021.768685
work_keys_str_mv AT shojaeifarbod hbi8000huyabioleadclinicalprogramisaselectivehistonedeacetylaseinhibitorwiththerapeuticbenefitsinleukemiaandinsolidtumors
AT goodenowbob hbi8000huyabioleadclinicalprogramisaselectivehistonedeacetylaseinhibitorwiththerapeuticbenefitsinleukemiaandinsolidtumors
AT leegloria hbi8000huyabioleadclinicalprogramisaselectivehistonedeacetylaseinhibitorwiththerapeuticbenefitsinleukemiaandinsolidtumors
AT kabbinavarfairooz hbi8000huyabioleadclinicalprogramisaselectivehistonedeacetylaseinhibitorwiththerapeuticbenefitsinleukemiaandinsolidtumors
AT gillingsmireille hbi8000huyabioleadclinicalprogramisaselectivehistonedeacetylaseinhibitorwiththerapeuticbenefitsinleukemiaandinsolidtumors

Ejemplares similares